12 Best Medical Stocks To Buy Under $20

Page 7 of 11

5. Amicus Therapeutics Inc. (NASDAQ:FOLD)

Share Price as of January 8: $9.46

Number of Hedge Fund Holders: 38

Amicus Therapeutics Inc. (NASDAQ:FOLD) is an American biopharmaceutical company that specializes in developing and commercializing innovative treatments for rare diseases. The company’s primary focus is on orphan diseases, which often lack effective therapies, making its work vital for patients in need.

The company’s strategic focus on rare diseases positions it favorably within the medical market. Amicus Therapeutics Inc. (NASDAQ:FOLD) is advancing its work to establish leadership in treating both Fabry and Pompe diseases. The company has managed to significantly increase its revenues with a strong commitment to innovation and patient care.

In the third quarter of 2024, Amicus Therapeutics Inc. (NASDAQ:FOLD) reported total revenues of $141.5 million, marking a 37% increase year-over-year. The revenue from the company’s flagship product, Galafold, reached $120.4 million, up 20% compared to the previous year. Galafold is an oral treatment for Fabry disease that stabilizes a dysfunctional enzyme in patients with specific genetic variants. This product has demonstrated strong demand and market presence. Amicus Therapeutics Inc. (NASDAQ:FOLD) has also recently launched Pombiliti and Opfolda, a two-component therapy for Pompe disease, which generated $21.1 million in revenue during Q3 2024. This marks a 33% increase from the second quarter of 2024.

Page 7 of 11